Skip to main content

Published locations for Risk for vascular adverse events higher with nilotinib vs. imatinib in patients with CML

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Risk for vascular adverse events higher with nilotinib vs. imatinib in patients with CML

User login

  • Reset your password
  • /content/risk-vascular-adverse-events-higher-nilotinib-vs-imatinib-patients-cml
  • /hematology-oncology/article/246640/cml/risk-vascular-adverse-events-higher-nilotinib-vs-imatinib